A Boston Globe investigation, reported via STAT, says Boston Scientific keeps promoting its Watchman cardiac implant despite setbacks, after spending hundreds of millions on it and a long FDA debate that yielded approval only for a limited patient group. The company then aimed to expand use beyond t